Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TransMedics (TMDX) Shares Outstanding (Diluted Average) (2020 - 2024)

TransMedics has reported Shares Outstanding (Diluted Average) over the past 5 years, most recently at $35.7 million for Q3 2024.

  • Quarterly results put Shares Outstanding (Diluted Average) at $35.7 million for Q3 2024, up 9.41% from a year ago — trailing twelve months through Sep 2024 was $35.7 million (up 9.41% YoY), and the annual figure for FY2023 was $32.5 million, up 10.02%.
  • Shares Outstanding (Diluted Average) for Q3 2024 was $35.7 million at TransMedics, up from $35.3 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for TMDX hit a ceiling of $35.7 million in Q3 2024 and a floor of $21.2 million in Q1 2020.
  • Median Shares Outstanding (Diluted Average) over the past 5 years was $28.0 million (2022), compared with a mean of $29.1 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): grew 28.96% in 2021 and later grew 1.78% in 2022.
  • TransMedics' Shares Outstanding (Diluted Average) stood at $24.7 million in 2020, then grew by 11.8% to $27.6 million in 2021, then increased by 7.02% to $29.6 million in 2022, then rose by 10.02% to $32.5 million in 2023, then rose by 9.74% to $35.7 million in 2024.
  • The last three reported values for Shares Outstanding (Diluted Average) were $35.7 million (Q3 2024), $35.3 million (Q2 2024), and $34.7 million (Q1 2024) per Business Quant data.